These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17291290)

  • 21. Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes.
    Glas R; Franksson L; Ohlén C; Höglund P; Koller B; Ljunggren HG; Kärre K
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11381-5. PubMed ID: 1454824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8+ T cells in autoimmunity.
    Walter U; Santamaria P
    Curr Opin Immunol; 2005 Dec; 17(6):624-31. PubMed ID: 16226438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.
    Demotte N; Stroobant V; Courtoy PJ; Van Der Smissen P; Colau D; Luescher IF; Hivroz C; Nicaise J; Squifflet JL; Mourad M; Godelaine D; Boon T; van der Bruggen P
    Immunity; 2008 Mar; 28(3):414-24. PubMed ID: 18342010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development.
    Ford MS; Chen W; Wong S; Li C; Vanama R; Elford AR; Asa SL; Ohashi PS; Zhang L
    Eur J Immunol; 2007 Aug; 37(8):2234-41. PubMed ID: 17578845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of HLA class I-specific inhibitory receptors by chronically activated cytolytic T lymphocytes: useful or harmful to the host?
    Mingari MC; Ponte M; Vitale C; Schiavetti F; Bertone S; Moretta L
    Melanoma Res; 1997 Aug; 7 Suppl 2():S89-93. PubMed ID: 9578422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for a major histocompatibility complex class Ib-restricted T cell response.
    Hoare HL; Sullivan LC; Pietra G; Clements CS; Lee EJ; Ely LK; Beddoe T; Falco M; Kjer-Nielsen L; Reid HH; McCluskey J; Moretta L; Rossjohn J; Brooks AG
    Nat Immunol; 2006 Mar; 7(3):256-64. PubMed ID: 16474394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
    Ramanathan S; Gagnon J; Ilangumaran S
    Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells.
    Westendorf AM; Fleissner D; Groebe L; Jung S; Gruber AD; Hansen W; Buer J
    Gut; 2009 Feb; 58(2):211-9. PubMed ID: 18832523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
    Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
    Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymic microenvironments for T-cell repertoire formation.
    Nitta T; Murata S; Ueno T; Tanaka K; Takahama Y
    Adv Immunol; 2008; 99():59-94. PubMed ID: 19117532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
    Khadra A; Santamaria P; Edelstein-Keshet L
    J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
    Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells.
    Poggi A; Zocchi MR
    Hum Immunol; 2008 Nov; 69(11):755-9. PubMed ID: 18817823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells.
    Itsumi M; Yoshikai Y; Yamada H
    Eur J Immunol; 2009 Jul; 39(7):1784-93. PubMed ID: 19544306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral tolerance in CD8+ T cells.
    Srinivasan M; Frauwirth KA
    Cytokine; 2009 May; 46(2):147-59. PubMed ID: 19268604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
    Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development.
    Setoguchi R; Tachibana M; Naoe Y; Muroi S; Akiyama K; Tezuka C; Okuda T; Taniuchi I
    Science; 2008 Feb; 319(5864):822-5. PubMed ID: 18258917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.